CEL-SCI Corporation (CVM)
CEL-SCI Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Vienna, VA, US. The stock last traded at $1.47, down 3.62% on the session, giving a market capitalisation of $10.1M. On trailing twelve-month figures it carries a trailing P/E of -0.42, a net margin of 0.0%. Its beta of 0.56 implies it has historically moved less than the broad market.
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
CEL-SCI Corporation is most often compared with the following Healthcare names: